linkedin
 
You Are On
Equity
Equity Analysis
News Analysis
Corporate Action
Corporate Info
Derivatives
Other Market
Research
 
 Directors Report  
Concord Biotech Ltd.
 
March 2021

Description of state of companies affair

The first phase expansion of the API facility has been successfully completed and this plant will start contributing to the sales in the current financial year. The augmented capacity will go a long way in meeting the increased demand for the API’s and also help Company to expand its portfolio. During the financial year 2020-21, Company achieved a sales of Rs. 60,351.45 lacs showing a growth of 21.14% over the previous year. With Company’s product getting registration in various countries and increased penetration in the domestic market, which though was impacted by the Covid-19 situation, the formulation business is showing stable growth.

Details regarding energy conservation

Information pursuant to clause (m) sub-section (3) of section 134 of The Companies Act, 2013 read with the Companies (Accounts) Rules, 2014 and forming part of this report are given in the Annexure II.

Details regarding technology absorption

Information pursuant to clause (m) sub-section (3) of section 134 of The Companies Act, 2013 read with the Companies (Accounts) Rules, 2014 and forming part of this report are given in the Annexure II.

Details regarding foreign exchange earnings and outgo

The details of foreign exchange earnings and outgo are annexed in Annexure II.

Disclosures in director’s responsibility statement

Pursuant to Section 134(3)(c) of the Companies Act, 2013 the Directors confirm the following: i. In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures. ii. Your Directors had selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period. iii. Your Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities. iv. Your Directors had prepared the attached Annual Accounts for the year ended March 31, 2020 on a going concern basis. v. Your Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

 
RMS | Policies & Procedures| PMLA | Disclaimer | Privacy Policy | Web Mail | Relationship | Investor Grievance
Career | Contact Us| KYC| PMS Risk Disclosure | Key Managerial Person | Basic Details | Process of Opening an Account | Process of Filing Complaint
Links to MCX | NCDEX |FMC | NCDEX CMID NCDEX-CO-04-00129 | MCX 10550 | FMC MCX: MCX/TCM/CORP/0008| FMC NCDEX : NCDEX/TCM/CORP/0274    
NSE: INB230914036 |NSE F & O INF230914036 |BSE: INB010914032 |BSE F & O: INF010914032 | CDSL: IN-DP-CDSL-335-2006 | OTC: INB200914032
Related Sites: Bombay Stock Exchange (BSE), Investor Protection, National Stock Exchange (NSE), Securities & Exchange Board of India (SEBI)
© Padmakshi 2009. All Rights Reserved. Designed || Developed & Content Powered By Accord Fintech Pvt. Ltd.